1,626 results on '"Maziarz, Richard T."'
Search Results
2. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
3. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation
4. “Don't keep me waiting”: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes
5. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome
6. Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective
7. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
8. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year
9. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
10. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
11. Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques
12. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
13. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
14. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
15. Serial Transthoracic Ultrasonography Studies in Hematopoietic Cell Transplant Patients: A Tool for Early Lung Pathology Detection
16. Management of Immune Compromised Transplant and Immune Effector Cell Treated Patients in the Setting of the COVID-19 Viral Pandemic: The OHSU Experience
17. Mesenchymal Stromal Cells: Impact on Hematopoietic Cell Transplantation
18. Hematopoietic Stem Cell Sources and Donor Selection
19. Immune Reconstitution
20. Overview of Hematopoietic Cell Transplantation and Cellular Therapy
21. Acute Lymphoblastic Leukemia
22. Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.
23. The rationale behind grafting haploidentical hematopoietic stem cells
24. Don't keep me waiting: estimating the lifetime impact of reduced vein-to-vein time for CAR-T treated patients with LBCL
25. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
26. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups
27. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
28. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
29. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis
30. Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL
31. Lifetime Costs for Treated Follicular Lymphoma Patients in the US
32. Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations
33. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma
34. The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients
35. Access to Allogeneic Hematopoietic Cell Transplant for Patients with Hematologic Malignancies in Oregon
36. JAK1 Inhibition during CAR-T Cell Treatment Results in Reduction in Various Cytokines That Correlate with Cytokine Release Syndrome (CRS) and Immune Effector Cell (IEC)–Associated Neurotoxicity Syndrome (ICANS) Grades
37. Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open-Label Expanded Access Program (EAP)
38. Impact of ABO Compatibility on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT): Ptcy Impacts Platelet Engraftment, Independent of ABO Compatibility
39. Long-Term Durable Responses in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL) Treated with Tisagenlecleucel and Its Association with Persistence of Chimeric Antigen Receptor (CAR) T Cells
40. Discovery of an Inherited Variant Associated with Susceptibility to Secondary Acute Lymphoblastic Leukemia (ALL) after Lenalidomide Maintenance and Autologous HCT for Multiple Myeloma (MM)
41. The Impact of Telehealth Visits on Access to Transplant Care for Recipients of Allogeneic Hematopoietic Cell Transplantation in the State of Oregon
42. Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel: A Cell Therapy Consortium Study
43. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102
44. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
45. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome
46. Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient
47. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
48. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma
49. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS
50. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.